{
    "clinical_study": {
        "@rank": "105777", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "90 mg Ticagrelor"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "75mg Clopidogrel"
            }
        ], 
        "brief_summary": {
            "textblock": "Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12\n      Receptor Inhibition Effects of Ticagrelor and Clopidogrel"
        }, 
        "brief_title": "A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese\n      Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female Vietnamese patients (as confirmed by the Principal Investigator) aged\n             >18 years with suitable veins for cannulations or repeated venipunctures and stable\n             coronary heart disease\n\n          -  Stable use of aspirin 75 to 100 mg daily for at least the preceding 2 weeks and which\n             will be continued throughout the study period\n\n          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive\n\n          -  Women must have a negative urine pregnancy test at Visit 1\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the investigator, may either put the patient at risk because of participation in the\n             study, or influence the results or the patient's ability to participate in the study\n\n          -  Unstable angina or any clinically significant illness, medical/surgical procedure or\n             trauma within 4 weeks of the first administration of IP\n\n          -  Patients who had acute coronary syndrome or stent placed within 12 months of\n             screening\n\n          -  Planned arterial revascularization\n\n          -  Current use of ADP receptor blockers (eg, clopidogrel, ticlopidine, prasugrel),\n             dipyridamole or cilostazol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757262", 
            "org_study_id": "D5130C00078"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor", 
                "description": "Morning and Evening dose for 5 days", 
                "intervention_name": "90 mg Ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "description": "Morning dose for 5 days", 
                "intervention_name": "75mg Clopidogrel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Coronary Heart Disease", 
        "lastchanged_date": "May 10, 2013", 
        "number_of_arms": "2", 
        "official_title": "Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study", 
        "overall_official": [
            {
                "affiliation": "National Heart Institute, Bach Mai Hospital, Vietnam", 
                "last_name": "Nguyen Lan Viet, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Astrazeneca, Wilmington, US", 
                "last_name": "Judith Hsia, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Astrazeneca, Molndal, Sweden", 
                "last_name": "Miriana Kujacic, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health - Vietnam"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacodynamics of Ticagrelor on P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5"
            }, 
            {
                "measure": "Pharmacodynamics of Clopidogrel P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)]", 
                "safety_issue": "No", 
                "time_frame": "Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety profile in terms of adverse events, blood pressure, pulse, ECG (Electrocardiogram),  physical examination, and safety laboratory variables", 
            "safety_issue": "Yes", 
            "time_frame": "From screening to followup (8 weeks)"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}